Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
Close

Search

  • https://www.facebook.com/
  • https://twitter.com/
  • https://t.me/
  • https://www.instagram.com/
  • https://youtube.com/
Subscribe
Home/News/Moderna’s Shocking Setback: FDA Rejects Critical Review of Revolutionary Flu Shot
News

Moderna’s Shocking Setback: FDA Rejects Critical Review of Revolutionary Flu Shot

By adminitfy
February 11, 2026 2 Min Read

Moderna Inc. has encountered a significant setback as the Food and Drug Administration (FDA) has declined to initiate a review of its application for an experimental flu vaccine, known as mRNA-1010. The company announced this news on Tuesday, March 26, 2024, leading to an approximately 7% drop in its stock during after-hours trading.

Moderna asserts that the FDA’s decision contradicts earlier feedback received prior to the submission of the application and the initiation of Phase 3 trials for the vaccine. In response, Moderna has sought a meeting with the FDA to clarify the path forward. Notably, the FDA did not cite any specific safety or efficacy concerns regarding the vaccine; instead, the agency expressed reservations about the study design, which had been previously approved.

Despite this setback, Moderna maintains that this ruling will not affect its financial projections for 2026. The company’s Phase 3 trial data released last year were promising, successfully meeting all trial objectives. According to Moderna, this standalone flu shot is pivotal to their strategy of developing a combined vaccine targeting both influenza and COVID-19.

The FDA’s decision highlights broader shifts in U.S. immunization policies, particularly under the leadership of Health and Human Services Secretary Robert F. Kennedy Jr., known for his vaccine skepticism. Moderna also pointed to the return of Vinay Prasad, the FDA’s top vaccine regulator, as a significant factor in this tightening of vaccine regulations. Prasad, who heads the Center for Biologics Evaluation and Research (CBER), has been critical of approval processes and has previously linked adverse outcomes to COVID vaccines.

In a letter dated February 3, Prasad indicated that the FDA’s refusal stemmed from objections to the design of Moderna’s clinical trial, particularly noting that the comparison of its product to an approved flu vaccine did not reflect the best available standard of care. Consequently, the FDA deemed the study inadequate and not well-controlled.

Moderna disputes this reasoning, arguing that existing FDA guidelines do not mandate using the most advanced vaccine as a comparator in clinical studies. “This decision by CBER, which did not identify any safety or efficacy concerns with our product, does not further our shared goal of enhancing America’s leadership in developing innovative medicines,” stated Moderna CEO Stéphane Bancel. He emphasized that conducting a comprehensive review of their flu vaccine submission should not be a contentious issue, especially given that the study approach had been discussed and approved by CBER prior to the start of trials.

Looking ahead, Moderna anticipates that the earliest potential approval for its flu vaccine might occur in late 2026 or late 2027, depending on regulatory reviews in the U.S., Europe, Canada, and Australia. The FDA, however, has a policy of not commenting on regulatory communications directed toward individual sponsors.

As this situation unfolds, Moderna and other stakeholders in the vaccine development landscape will be closely monitoring how regulatory policies continue to evolve, and what that may mean for future immunization strategies and innovations in public health.

Original Source: https://www.cnbc.com/2026/02/10/moderna-fda-flu-shot.html
Category :
Tags:
Publish Date: 2026-02-11 04:41:00

Author

adminitfy

Follow Me
Other Articles
Repeated Quakes Keep West Sikkim Awake; Residents Seek Safety
Previous

Repeated Quakes Keep West Sikkim Awake; Residents Seek Safety

Next

TMC Controversy in Shillong — Exclusive Report by The Shillong Times

No Comment! Be the first one.

Leave a Reply Cancel reply

You must be logged in to post a comment.

Search...

Recent Posts

  • Tura Civil Hospital Achieves Rare Diaphragmatic Hernia Surgery First
    Tura Civil Hospital Achieves Rare Diaphragmatic Hernia Surgery First
    by adminitfy
    November 22, 2026
  • Empowering Northeast India: CII’s CSR Connect Event Ignites Social Development
    by adminitfy
    July 3, 2024
  • Urgent Crisis: Northeast on High Alert as Death Toll Tragically Rises in Assam
    by adminitfy
    July 3, 2024
  • Triumphant Breakthrough: Security Forces Successfully Capture 4 Insurgents in Manipur Operation
    by adminitfy
    July 3, 2024

Welcome to the ultimate source for fresh perspectives! Explore curated content to enlighten, entertain and engage global readers.

  • Facebook
  • X
  • Instagram
  • LinkedIn

Latest Posts

  • Tura Civil Hospital Achieves Rare Diaphragmatic Hernia Surgery First
  • The AAA Ownership Gap: Why India Builds Worlds It Doesn’t Own
  • Dhubri Bar Election: Record 91% Turnout, Ahmed Elected President
  • Assam Fake Certificate Crackdown: 75+ Nagaon Schools File FIRs
  • Trump Orders Contractors to Seek White House Approval Before Congress
  • November 2026 (687)
  • October 2026 (646)
  • September 2026 (524)
  • August 2026 (1001)
  • July 2026 (986)
  • June 2026 (963)
  • May 2026 (922)
  • April 2026 (1525)
  • March 2026 (1522)
  • February 2026 (1252)
  • January 2026 (968)
  • December 2025 (942)
  • November 2025 (853)
  • October 2025 (869)
  • September 2025 (733)
  • August 2025 (810)
  • July 2025 (720)
  • June 2025 (1244)
  • May 2025 (2201)
  • April 2025 (1481)
  • March 2025 (2020)
  • February 2025 (1159)
  • January 2025 (1440)
  • December 2024 (1499)
  • November 2024 (1771)
  • October 2024 (1815)
  • September 2024 (1750)
  • August 2024 (1458)
  • July 2024 (1268)

Contact

Email

info@itfy.in

Location

INDIA

Copyright 2026 — Itfy.in. All rights reserved.